Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Respiratory Disease

Respiratory Disease

17 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Respiratory Disease

28 trials tracked for Respiratory Disease: 5 in phase 3 or 4 and 3 with published results. The most-cited published study has 430 citations.

28Trials tracked
5Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 2 Phase 2 8 Phase 1 3 Other / NA 12
  1. Phase 3 Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease Completed · 430 cited
  2. Phase 4 Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Completed · 125 cited
  3. Phase 4 The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 Completed · 1 cited
  4. Phase 4 Treatment of Acute Sinusitis Completed
  5. Phase 3 Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI Completed
  6. Phase 2 Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis Completed
Show 22 more trials
  1. Phase 2 A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction. Completed
  2. Phase 2 Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine Completed
  3. Phase 2 Vitamin D for Sickle-cell Respiratory Complications Completed
  4. Phase 2 A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine Completed
  5. Phase 2 A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response. Completed
  6. Phase 2 University of Wisconsin Meditation & Exercise Cold Study Completed
  7. Phase 2 Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection Completed
  8. Phase 1 A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults. Completed
  9. Phase 1 A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults Completed
  10. Phase 1 Study to Evaluate the AIO-001 in Healthy Participants Completed
  11. N/A A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD Completed
  12. N/A Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly Completed
  13. N/A Utility of Continuous Pulse Oximetry for Pediatric Patients With Stable Respiratory Illness Completed
  14. N/A Prophylactic Efficacy of Relenza Against Influenza A and B Completed
  15. N/A Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway Completed
  16. N/A Initial Specialist Telephone Consultation With New Patients in Secondary Care Completed
  17. N/A Comparing 6-Minute Walk Tests for Ambulatory Oxygen Assessment Completed
  18. N/A A Comparative Clinical Trial of the TensorTip, a Novel Non Invasive Device for Measurement Blood Parameters Completed
  19. N/A Engineering Evaluation of the Helix Ventilator Completed
  20. N/A Timing of Planned Caesarean Section and Morbidity of the Newborn Completed
  21. N/A Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific Completed
  22. N/A FluSAFE: Flu SMS Alerts to Freeze Exposure Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mathematical modelling review quantifies ethnic disparities in respiratory infection transmission dynamics across England
Infectious Disease
Mathematical modelling review quantifies ethnic disparities in respiratory infection transmission dynamics across England Why Some Groups Catch More Viruses Than Others
This mathematical modelling review synthesizes data from the 2024-2025 Reconnect social contact survey involving 12,484 participants in Engl…
Where you live and who you meet changes your risk of catching a respiratory virus.
medRxiv Apr 21, 2026
Hospital at home reduces length of stay and 30-day readmissions in patients with heart, airway, or respiratory conditions
Pediatrics Cohort
Hospital at home reduces length of stay and 30-day readmissions in patients with heart, airway, or respiratory conditions Could keeping sick patients at home save days in the hospital and lower costs?
A retrospective cohort study in England of 2,972 HAH episodes and matched inpatient controls found HAH reduced length of stay by 3.13 days a…
Hospital at home care in England cut hospital stays by over 3 days and lowered 30-day readmission rates by nearly half compared to tradition…
Frontiers Apr 14, 2026
Openness-based psychoeducational booklet improved SGRQ activities in chronic respiratory disease patients during inpatient pulmonary rehabilitation
Primary Care & Family Medicine RCT
Openness-based psychoeducational booklet improved SGRQ activities in chronic respiratory disease patients during inpatient pulmonary rehabilitation Openness booklet improved activity scores in pulmonary rehab patients
This randomized controlled trial enrolled 136 participants with chronic respiratory disease undergoing inpatient pulmonary rehabilitation.
An openness-focused booklet helped pulmonary rehab patients improve their ability to perform daily activities, even though their overall qua…
Apr 6, 2026
DaRRE strategy implemented in Kenya for respiratory disease outbreak response
Infectious Disease
DaRRE strategy implemented in Kenya for respiratory disease outbreak response Kenya tests new strategy to detect and respond to respiratory disease outbreaks
A strategy for Detection and Response to Respiratory Events (DaRRE) was implemented in Kenya.
Kenya pilots a new strategy to help health officials find and respond to respiratory disease outbreaks more effectively.
CDC Apr 6, 2026
Surveillance report describes respiratory virus patterns in children with acute respiratory illnesses
Pediatrics
Surveillance report describes respiratory virus patterns in children with acute respiratory illnesses U.S. surveillance tracks respiratory viruses in children with acute illnesses
A surveillance report from the United States describes respiratory virus patterns among children with acute respiratory illnesses.
U.S. health officials are tracking respiratory viruses in sick children to watch for patterns, but this report offers no new medical guidanc…
CDC Apr 4, 2026

Questions about Respiratory Disease

Do cohort studies show clinical outcomes for pediatric acute respiratory infections?

Yes, cohort studies are the most common study type in pediatric ARI research, providing key data on pathogen profiles, co-infections, seasonal patterns, and clinical outcomes like hospitalization and severity.

Full answer →
How does chronic air pollution affect children and older adults in Puerto Rico?

Chronic air pollution in Puerto Rico increases risks of cancer, respiratory, and cardiovascular diseases, especially in children and older adults, through microbiome disruption and immune dysregulation.

Full answer →